Advanced Colorectal Cancer
Carcinoma of the Rectosigmoid Colon
Female, 54 years
Patient Internal ID: 582221397
ICD-10 code
C19 Malignant Neoplasm of the Rectosigmoid Junction of the Colon
Diagnosis (Incl. Metastases/Stage) and Year
December 2019
Carcinoma of the Rectosigmoid part of the Colon pT4apN1aM0 pLVI 0 G3, Stage III, KRAS Gene Mutation (exon 2).
In October 2020 disease progression – Metastasis in the Lungs.
Previous Treatment
Surgery (Resection of Rectum), Chemotherapy (Capecitabine + Oxaliplatin), Surgery (Resection of Lung Metastasis), Chemotherapy (Fluorouracil + Irinotecan), Target Therapy (Bevacizumab).
Prognosis and Survival Expectation
The prognosis remains poor, with a median survival of 30 months from diagnosis and a relative 5-year survival rate of about 14%.
Treatment Provided
Autologous DCV (5 doses) over a period of 5 months.
Patient Survival/Condition and Year
Date of Review: 01/12/2023
The patient has survived for 42 months since the diagnosis and 32 months since the disease progression. It can be concluded that the addition of Immunotherapy, alongside Surgery, Chemotherapy and Target Therapy, has extended patient survival by 12 months.
